Back to Search
ROY LAUFER, MD
MD
Internal Medicine Physician
NPI: 1447214879Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
1569431(NY)
Research & Publications (20)
Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate.
PMID 19569735·Xenobiotica·2009
7-preclinical
Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine.
PMID 19493593·Eur J Med Chem·2009
7-preclinical
Synthesis and evaluation of novel phosphoramidate prodrugs of 2'-methyl cytidine as inhibitors of hepatitis C virus NS5B polymerase.
PMID 19181520·Bioorg Med Chem Lett·2009
4-observational
Quantitative prediction of human clearance guiding the development of Raltegravir (MK-0518, isentress) and related HIV integrase inhibitors.
PMID 19144773·Drug Metab Dispos·2009
7-preclinical
Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.
PMID 18952417·Bioorg Med Chem Lett·2008
8-other
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
PMID 18763751·J Med Chem·2008
8-other
Palladium-catalyzed direct heck arylation of dual pi-deficient/pi-excessive heteroaromatics. Synthesis of C-5 arylated imidazo[1,5-a]pyrazines.
PMID 18576663·Org Lett·2008
8-other
Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors.
PMID 18217703·J Med Chem·2008
7-preclinical
A biogenetically-inspired synthesis of a ring-D model of kinamycin F: insights into the conformation of ring D.
PMID 18183994·Org Lett·2008
8-other
Studies of metabolism and disposition of potent human immunodeficiency virus (HIV) integrase inhibitors using 19F-NMR spectroscopy.
PMID 17896326·Xenobiotica·2007
7-preclinical
Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones.
PMID 17824681·J Med Chem·2007
7-preclinical
Measurement of K-27, an oxime-type cholinesterase reactivator by high-performance liquid chromatography with electrochemical detection from different biological samples.
PMID 17603065·J Chromatogr A·2007
7-preclinical
High-throughput radiometric CYP2C19 inhibition assay using tritiated (S)-mephenytoin.
PMID 17600081·Drug Metab Dispos·2007
8-other
Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors.
PMID 17428043·J Med Chem·2007
7-preclinical
4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species.
PMID 17154493·J Med Chem·2006
7-preclinical
[Effect of nociceptin on histamine and serotonin release in the central nervous system].
PMID 17094659·Acta Pharm Hung·2006
7-preclinical
[Endogenous nociceptin level in ischemic stroke: connection to serotonin system].
PMID 17073212·Neuropsychopharmacol Hung·2006
8-other
A structure-guided approach to an orthogonal estrogen-receptor-based gene switch activated by ligands suitable for in vivo studies.
PMID 16942012·J Med Chem·2006
8-other
Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects.
PMID 16926632·Anticancer Drugs·2006
7-preclinical
Development of humanized mice for the study of hepatitis C virus infection.
PMID 16757300·Transplant Proc·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2524 W 2ND ST
BROOKLYN, NY 11223 - Phone
- (718) 336-9163
Quick Facts
- NPI
- 1447214879
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile